Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 2/27/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Arthur T. Sands Ph.D.

Wrong Dr. Arthur T. Sands Ph.D.?

Chief Executive Officer

Local Address: The Woodlands, Texas, United States
Nurix Inc
1700 Owens Street, Suite 290
San Francisco , California 94158
United States

Company Description: Nurix, Inc. is a leader in discovering and developing a new class of drugs that work by modulating the protein regulation machinery of the cell. The Nurix...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • B.A. , economics and political science
    Yale University
  • Ph.D
  • Ph.D.
    Baylor College of Medicine
  • M.D.
    Baylor College of Medicine
153 Total References
Web References
Nurix | Board Of Directors
www.nurix-inc.com, 27 Feb 2015 [cached]
Arthur T. Sands, M.D., Ph.D. Chief Executive Officer and Board Director
Arthur T. Sands, M.D., Ph.D., serves as the Chief Executive Officer at Nurix and is a member of the company's board of directors. Prior to joining Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals and served as President, Chief Executive Officer and a Director since 1995. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery and guided the evolution of Lexicon from a research-stage company to a drug development company, catalyzed by numerous alliances with Bristol Myers Squibb, Takeda and Genentech, and generating more than $450 million in revenue. Dr. Sands serves as Adjunct Professor in the Department of Human and Molecular Genetics at Baylor College of Medicine. He has also published many scientific and medical articles and is an inventor on numerous patents related to the discovery of human genes and their use in the development of new therapies. Dr. Sands holds an M.D. and a Ph.D. from Baylor College of Medicine and a B.A. in economics and political science from Yale University.
Board of Directors - BioHouston
www.biohouston.org, 5 Nov 2014 [cached]
Arthur T. Sands M.D., Ph.D., CEO, Nurix, Inc.
Nurix Names Arthur T. ...
www.fiercebiotech.com, 18 Sept 2014 [cached]
Nurix Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer Share Tools Print
Nurix Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer
SAN FRANCISCO, Calif. - September 18, 2014 - Nurix, Inc., a leader in discovering and developing therapies that modulate the ubiquitin proteasome system (UPS), announced today the appointment of Arthur T. Sands, M.D., Ph.D., as chief executive officer. Dr. Sands succeeds interim chief executive officer Mark A. Goldsmith, M.D., Ph.D., a partner at Third Rock Ventures, who will continue service to the company as chairman of its board of directors.
...
"I am delighted to join Nurix at this point in the company's evolution as it establishes a broadly applicable platform in drug discovery based on its innovative research on the selective modulation of ubiquitin ligases for breakthrough applications in cancer and other diseases," said Dr. Sands. "Nurix has already built a strong foundation with world-renowned founders, collaborators and an outstanding scientific team. I would like to thank Mark for his leadership since the inception of the Company, and look forward to working with him, Nurix's board of directors and its growing team on behalf of patients with life-threatening diseases."
Prior to joining Nurix, Dr. Sands co-founded Lexicon Pharmaceuticals (Nasdaq: LXRX) and served as president, chief executive officer and a director since 1995. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery and guided the evolution of Lexicon from a research-stage company to a drug development company, catalyzed by numerous alliances with Bristol Myers Squibb, Takeda and Genentech, and generating more than $450 million in revenue. Lexicon's independently developed product portfolio, now approaching late stage development and commercialization, includes small molecules directed to novel targets for treatment of carcinoid syndrome, type 1 diabetes and type 2 diabetes. Dr. Sands serves as adjunct professor in the Department of Human and Molecular Genetics at Baylor College of Medicine. He has also published many scientific and medical articles and is an inventor on numerous patents related to the discovery of human genes and their use in the development of new therapies. Dr. Sands holds an M.D. and a Ph.D. from Baylor College of Medicine and a B.A. in economics and political science from Yale University.
>Nurix has named Dr. Arthur ...
www.fiercebiotech.com, 19 Sept 2014 [cached]
>Nurix has named Dr. Arthur Sands as chief executive officer. Release
Management Team | About Us
www.lexicon-genetics.com, 3 July 2014 [cached]
Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer
...
Arthur Sands
Dr. Sands co-founded Lexicon and has been our president and chief executive officer and a director since September 1995. At Lexicon, Dr. Sands pioneered the development of large-scale gene knockout technology for use in drug discovery to bring innovative drugs to patients. He has overseen the evolution of Lexicon from a research-stage company to a drug development company, including implementing the strategy to integrate chemistry capabilities with Lexicon's powerful genetics platform to create a unique drug discovery engine. Dr. Sands was also instrumental in establishing Lexicon's major alliances with pharmaceutical companies as well as implementing the company's financing strategy.
...
Before founding Lexicon, Dr. Sands served as an American Cancer Society postdoctoral fellow in the Department of Human and Molecular Genetics at Baylor College of Medicine. He received his B.A. in economics and political science from Yale University and his M.D. and Ph.D. from Baylor College of Medicine where he studied gene knockout technology and tissue-specific gene regulation in transgenic mice.
...
With Dr. Sands, he has co-authored numerous scientific and drug development publications focusing on gene knockout technology and drug discovery.
Other People with the name "Sands":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304